Literature DB >> 27587715

Pilot evaluation of short-term changes in macular pigment and retinal sensitivity in different phenotypes of early age-related macular degeneration after carotenoid supplementation.

Federico Corvi1,2, Eric H Souied1, Yousra Falfoul1, Anouk Georges1, Camille Jung3, Lea Querques2, Giuseppe Querques1,2.   

Abstract

PURPOSE: To investigate the response of carotenoid supplementation in different phenotypes of early age-related macular degeneration (AMD) by measuring macular pigment optical density (MPOD) and retinal sensitivity.
METHODS: Consecutive patients with only medium/large drusen and only reticular pseudodrusen (RPD) and age-matched and sex-matched controls were enrolled. At baseline, participants underwent a complete ophthalmological examination including measurement of best-corrected visual acuity (BCVA), MPOD and retinal sensitivity. Patients were put on vitamin supplementation (lutein 10 mg/day, zeaxanthin 2 mg/day) and 3 months later underwent a repeated ophthalmological examination.
RESULTS: Twenty patients with medium/large drusen, 19 with RPD and 15 control subjects were included. At baseline, in controls, mean MPOD and BCVA were significantly higher compared with RPD (p=0.001 and p=0.01) but similar to medium/large drusen (p=0.9 and p=0.4). Mean retinal sensitivity was significantly higher in controls compared with RPD and medium/large drusen (for all p<0.0001). After 3 months of carotenoid supplementation the mean MPOD significantly increased in RPD (p=0.002), thus showing no more difference compared with controls (p=0.3); no significant changes were found in mean retinal sensitivity and BCVA (p=0.3 and p=0.7). Medium/large drusen did not show significant changes on MPOD, retinal sensitivity and BCVA (p=0.5, p=0.7 and p=0.7, respectively).
CONCLUSIONS: Patients with early AMD, especially RPD phenotype, show lower macular sensitivity and MPOD than controls. After supplementation, MPOD significantly increased in RPD. These results suggest different pathophysiology for RPD as compared with medium/large drusen and may open new ways to identifying further therapeutic targets in this phenotype of early AMD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  Macula; Retina; Treatment other

Mesh:

Substances:

Year:  2016        PMID: 27587715     DOI: 10.1136/bjophthalmol-2016-309115

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

Review 1.  Subretinal drusenoid deposits: An update.

Authors:  Manuel Monge; Adriana Araya; Lihteh Wu
Journal:  Taiwan J Ophthalmol       Date:  2022-05-26

2.  Exploring Reticular Pseudodrusen Extent and Impact on Mesopic Visual Sensitivity in Intermediate Age-Related Macular Degeneration.

Authors:  Himeesh Kumar; Robyn H Guymer; Lauren A B Hodgson; Xavier Hadoux; Zhichao Wu
Journal:  Invest Ophthalmol Vis Sci       Date:  2022-06-01       Impact factor: 4.925

Review 3.  Spotlight on reticular pseudodrusen.

Authors:  Alessandro Rabiolo; Riccardo Sacconi; Maria Vittoria Cicinelli; Lea Querques; Francesco Bandello; Giuseppe Querques
Journal:  Clin Ophthalmol       Date:  2017-09-20

4.  Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report.

Authors:  Marlene Saßmannshausen; Charlotte Behning; Ben Isselmann; Matthias Schmid; Robert P Finger; Frank G Holz; Steffen Schmitz-Valckenberg; Maximilian Pfau; Sarah Thiele
Journal:  Sci Rep       Date:  2022-09-02       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.